角膜新生血管治疗中以VEGF／VEGFR为靶点药物的研究进展  

Advances in anti-VEGF/VEGFR targeting drugs for corneal neovascularization

作　　者：王群[1,2] 黄一飞 

机构地区：[1]中国人民武装警察部队总医院眼科,北京100853 [2]解放军医学院

出　　处：《中华实验眼科杂志》2015年第12期1138-1143,共6页Chinese Journal Of Experimental Ophthalmology

基　　金：国家自然科学基金项目（81271052、31271059）;国家重点基础研究发展计划资助项目（2013CB967001）

摘　　要：角膜是眼屈光间质的重要组成部分，具有透明性、无血管性。透明角膜对维持眼视光功能十分重要。角膜的无血管状态是以低水平的血管生成因子和高水平的抗血管生成因子为基础。在病理情况下，角膜血管生成因子和抑制因子的平衡被打破，从而产生病理性角膜新生血管（corneal neovascularization，CNV）。血管内皮生长因子（VEGF）是目前已知促新生血管生成最主要的生长因子之一。近年来，VEGF和其受体的靶向抑制药物的有效性及安全性已经在部分新生血管性眼病如年龄相关性黄斑变性、糖尿病性视网膜病变、新生血管性青光眼、早产儿视网膜病变和CNV中得以证实。本文就CNV的抗VEGF及其受体靶向治疗药物的研究进展加以综述。Cornea is an important part of the refractive media. Healthy cornea is clear and avascular. Corneal avaseularity is necessary for the preservation of optimal vision and is maintained by a balance between angiogenic and antiangiogenic factors. In a variety of pathologic conditions,the balance between angiogenic and antiangiogenic factors may be tipped towards angiogenic molecules,leading to corneal neovaseularization （ CNV）. Recent research showed that vascular endothelial growth factor （VEGF） is an important factor responsible for CNV. Over the past several years,the safety and efficacy of several new agents targeting VEGF or VEGF receptor （VEGFR） have been verifies in many ocular neovascularization diseases such as age-related macular degeneration, diabetic retinopathy, neovascular glaucoma,retinopathy of prematurity and CNV. These agents not only have revolutionized the therapy of ocular neovaseularized disease but also have great potential for other blinding conditions such as CNV. These agents have great potential for the treatment of CNV. This article reviewed the most promising anti-VEGF/VEGFR therapies.

关 键 词：角膜新生血管 血管内皮生长因子 血管内皮生长因子受体 靶向药物 

分 类 号：R77[医药卫生—眼科]